ARDELYX, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
ARDELYX, INC. (ARDX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 1.07% for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-08.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2021-03-08
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2020-03-31 was 1.68%.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2014-06-30 was 1.76%.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2013-09-30 was 1.64%.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2020 was 1.07%, a 55.79% decline from fiscal 2019.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2019 was 2.42%, a 6.92% decline from fiscal 2018.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2018 was 2.60%, a 25.00% increase from fiscal 2017.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2017 was 2.08%, a 28.40% increase from fiscal 2016.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2020-12-31 | 1.07% 10-K · filed 2021-03-08 | |||
| 2020-06-30 | 1.33% 10-Q · filed 2020-08-06 | |||
| 2020-03-31 | 1.68% 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | 2.42% 10-K · filed 2020-03-06 | |||
| 2018-12-31 | 2.60% 10-K · filed 2019-03-06 | |||
| 2017-12-31 | 2.08% 10-K · filed 2019-03-06 | |||
| 2016-12-31 | 1.62% 10-K · filed 2019-03-06 | |||
| 2015-12-31 | 1.64% 10-K · filed 2018-03-14 | |||
| 2014-12-31 | 1.79% 10-K · filed 2017-02-17 | |||
| 2014-09-30 | 1.77% 10-Q · filed 2014-11-07 | |||
| 2014-06-30 | 1.76% 10-Q · filed 2014-08-08 | 1.77% 10-Q · filed 2014-08-08 | ||
| 2013-12-31 | 1.35% 10-K · filed 2016-03-04 | |||
| 2013-09-30 | 1.64% 10-Q · filed 2014-11-07 | 1.35% 10-Q · filed 2014-11-07 | ||
| 2013-06-30 | 1.05% 10-Q · filed 2014-08-08 | |||
| 2012-12-31 | 0.79% 10-K · filed 2015-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |